OCUL - Ocular Therapeutix Inc Stock Price, Fair Value and News

4.14USD-0.06 (-1.43%)Delayed as of 26 Apr 2024, 11:05 am ET

Market Summary

USD4.14-0.06

Delayedas of 26 Apr 2024, 11:05 am

-1.43%

OCUL Stock Price

View Fullscreen

OCUL RSI Chart

OCUL Valuation

Market Cap

624.2M

Price/Earnings (Trailing)

-7.73

Price/Sales (Trailing)

10.68

Price/Free Cashflow

-8.18

OCUL Price/Sales (Trailing)

OCUL Profitability

Return on Equity

-88.59%

Return on Assets

-32.03%

Free Cashflow Yield

-12.23%

OCUL Fundamentals

OCUL Revenue

Revenue (TTM)

58.4M

Rev. Growth (Yr)

5.16%

Rev. Growth (Qtr)

-1.85%

OCUL Earnings

Earnings (TTM)

-80.7M

Earnings Growth (Yr)

-88.01%

Earnings Growth (Qtr)

-5.6K%

Breaking Down OCUL Revenue

52 Week Range

2.787.96

(Low)(High)

Last 7 days

-28.5%

Last 30 days

-54.5%

Last 90 days

-10.1%

Trailing 12 Months

-30.3%

How does OCUL drawdown profile look like?

OCUL Financial Health

Current Ratio

6.66

Debt/Equity

0.1

Debt/Cashflow

-7.69

OCUL Investor Care

Shares Dilution (1Y)

91.75%

Diluted EPS (TTM)

-1.09

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	51.7M	54.6M	57.7M	58.4M
2022	49.4M	49.9M	49.7M	51.5M
2021	22.1M	32.3M	38.6M	43.5M
2020	6.3M	7.3M	12.3M	17.4M
2019	2.1M	2.1M	2.5M	4.2M
2018	1.8M	2.0M	2.0M	2.0M
2017	1.9M	1.9M	1.9M	1.9M
2016	1.8M	1.8M	1.8M	1.9M
2015	1.2M	1.5M	1.8M	1.8M
2014	200.5K	391.0K	581.5K	772.0K
2012	0	0	0	10.0K

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Ocular Therapeutix Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 26, 2024	summer road llc	bought	7,000,000	7.52	930,851	-
Feb 22, 2024	dugel pravin	acquired	-	-	854,979	executive chairman
Feb 22, 2024	nayak sanjay	acquired	-	-	80,300	chief strategy officer
Feb 05, 2024	mattessich antony c.	acquired	95,460	4.86	19,642	president and ceo
Feb 05, 2024	ozden rabia gurses	acquired	30,841	4.86	6,346	chief medical officer
Feb 05, 2024	notman donald	acquired	30,190	4.86	6,212	chief financial officer
Feb 05, 2024	strassburger philip c.	acquired	29,300	4.86	6,029	general counsel
Feb 05, 2024	white christopher g	acquired	28,722	4.86	5,910	chief business officer
Feb 03, 2024	notman donald	acquired	-	-	61,636	chief financial officer
Feb 03, 2024	white christopher g	acquired	-	-	39,980	chief business officer

Which funds bought or sold OCUL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 24, 2024	Simplicity Wealth,LLC	new	-	263,782	263,782	0.01%
Apr 24, 2024	Pegasus Partners Ltd.	sold off	-100	-111,500	-	-%
Apr 24, 2024	BROWN ADVISORY INC	unchanged	-	417,600	819,000	-%
Apr 24, 2024	DekaBank Deutsche Girozentrale	unchanged	-	431,000	892,000	-%
Apr 23, 2024	Global Retirement Partners, LLC	unchanged	-	1,103	2,048	-%
Apr 23, 2024	Gradient Investments LLC	sold off	-100	-4.00	-	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-64.8	-13,000	36,000	-%
Apr 22, 2024	Relyea Zuckerberg Hanson LLC	unchanged	-	81,664	160,160	0.03%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	53,655	181,290	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	added	51.17	1,199,410	1,774,800	-%

Are Funds Buying or Selling OCUL?

Are funds buying OCUL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own OCUL

No. of Funds

Unveiling Ocular Therapeutix Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 27, 2024	summer road llc	9.4%	14,360,633	SC 13D/A
Feb 14, 2024	opaleye management inc.	5.51%	6,070,000	SC 13G/A
Feb 13, 2024	vanguard group inc	4.46%	5,118,102	SC 13G/A
Jan 31, 2024	blackrock inc.	5.2%	5,761,533	SC 13G/A
Dec 28, 2023	venrock healthcare capital partners iii, l.p.	6.8%	7,775,760	SC 13G
Dec 22, 2023	deep track capital, lp	8.38%	9,230,769	SC 13G
Dec 18, 2023	summer road llc	11.6%	13,429,782	SC 13D/A
Feb 13, 2023	opaleye management inc.	7.89%	6,075,000	SC 13G/A
Feb 09, 2023	vanguard group inc	5.16%	3,976,853	SC 13G/A
Feb 01, 2023	blackrock inc.	6.4%	4,952,737	SC 13G/A

Recent SEC filings of Ocular Therapeutix Inc

View All Filings

Date Filed	Form Type	Document
Apr 19, 2024	PRE 14A	PRE 14A
Apr 18, 2024	8-K	Current Report
Mar 29, 2024	8-K	Current Report
Mar 25, 2024	S-3ASR	S-3ASR
Mar 11, 2024	10-K	Annual Report
Mar 11, 2024	8-K	Current Report
Mar 11, 2024	S-8	Employee Benefits Plan
Feb 27, 2024	4	Insider Trading
Feb 27, 2024	SC 13D/A	13D - Major Acquisition
Feb 26, 2024	3	Insider Trading

Peers (Alternatives to Ocular Therapeutix Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	40.6B	6.8B	-1.15%	-18.78%	-8.61	5.92	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.46%	-27.26%	-41.1	9.9	76.23%	61.08%
BMRN	15.5B	2.4B	-6.36%	-11.66%	92.47	6.41	15.42%	18.43%
INCY	11.5B	3.7B	-9.50%	-30.40%	19.23	3.11	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.85%	-43.46%	-10.93	14.57	425.83%	18.94%
BBIO	4.3B	-	-18.25%	70.26%	-6.55	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-6.76%	2.03%	-14.16	12.52	440.80%	-27.84%
ARWR	2.7B	240.7M	-21.52%	-38.49%	-9.13	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-8.32%	-19.69%	-43.85	3.7	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.79%	-8.36%	24.23	4.35	85.90%	-14.05%
NVAX	552.8M	983.7M	-16.14%	-47.54%	-1.01	0.56	-50.36%	17.16%
CRBP	351.2M	881.7K	-7.41%	335.24%	-7.87	466.16	-77.61%	-5.33%
INO	236.5M	4.9M	-18.26%	4.12%	-1.75	48.6	-54.97%	51.71%
IBIO	5.9M	2.1M	47.83%	55.96%	-0.22	2.14	-13.45%	66.37%

Ocular Therapeutix Inc News

Latest updates

Ocular Therapeutix Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-1.9%	14,802	15,081	15,186	13,374	14,076	11,965	12,266	13,187	12,309	12,153	11,718	7,342	7,349	5,876	1,569	2,609	2,256	829	650	492	504
Costs and Expenses	1.6%	34,851	34,295	35,756	35,923	33,437	33,509	32,182	31,020	30,358	31,682	31,949	27,570	21,692	19,882	19,453	19,223	23,657	23,973	22,249	20,150	17,787
S&GA Expenses	-0.7%	9,246	9,315	11,153	10,835	10,533	10,186	10,140	9,063	9,137	9,576	8,391	8,086	6,811	6,520	6,153	7,130	7,142	6,777	7,225	3,347	2,291
R&D Expenses	7.8%	16,195	15,019	15,094	14,747	13,543	13,719	13,100	13,100	12,578	12,719	13,859	10,927	7,624	6,951	8,021	6,098	10,125	10,235	9,414	11,317	10,258
Interest Expenses	21.2%	4,152	3,426	1,991	1,768	1,847	1,797	1,696	1,683	1,680	1,658	1,655	1,679	1,726	1,715	1,694	1,633	1,805	1,651	1,627	1,018	374
Net Income	-5562.8%	-29,220	-516	-20,682	-30,318	-15,542	-24,188	-18,766	-12,542	-3,850	2,657	-8,481	3,121	-85,612	-11,944	-36,568	-21,512	-26,017	-18,778	-24,453	-17,124	-17,399
Net Income Margin	-18.9%	-1.38*	-1.16*	-1.66*	-1.72*	-1.38*	-1.19*	-0.65*	-0.45*	-0.15*	-2.29*	-3.19*	-5.92*	-	-	-	-	-	-	-	-	-
Free Cashflow	-186.7%	-22,913	-7,991	-22,065	-23,352	-19,108	-13,963	-11,371	-18,876	-15,784	-13,258	-20,185	-17,517	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	55.2%	252	162	123	129	149	159	173	188	205	218	231	243	262	98.00	107	73.00	79.00	89.00	90.00	101	73.00
Current Assets	64.4%	232	141	101	107	130	146	160	175	191	204	217	228	246	82.00	90.00	55.00	60.00	70.00	65.00	79.00	56.00
Cash Equivalents	77.1%	196	111	67.00	79.00	102	121	135	145	164	179	192	209	230	71.00	84.00	48.00	56.00	65.00	62.00	76.00	61.00
Inventory	2.1%	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00
Net PPE	-6.0%	12.00	12.00	13.00	12.00	10.00	7.00	7.00	7.00	7.00	7.00	7.00	8.00	8.00	8.00	9.00	9.00	10.00	10.00	11.00	11.00	10.00
Liabilities	4.1%	161	155	119	119	114	112	107	108	117	130	150	160	186	102	102	84.00	82.00	77.00	81.00	76.00	37.00
Current Liabilities	-0.5%	35.00	35.00	32.00	30.00	31.00	29.00	26.00	24.00	26.00	25.00	22.00	27.00	27.00	23.00	14.00	11.00	12.00	11.00	10.00	9.00	9.00
Long Term Debt	4.3%	9.00	9.00	30.00	29.00	29.00	28.00	28.00	27.00	26.00	26.00	25.00	25.00	24.00	24.00	26.00	25.00	24.00	23.00	24.00	23.00	-
LT Debt, Non Current	4.3%	9.00	9.00	30.00	29.00	29.00	28.00	28.00	27.00	26.00	26.00	25.00	25.00	24.00	24.00	26.00	25.00	24.00	23.00	24.00	23.00	-
Shareholder's Equity	1060.5%	91.00	8.00	3.00	10.00	35.00	46.00	66.00	80.00	88.00	87.00	80.00	83.00	76.00	-	5.00	-	-	11.00	8.00	26.00	36.00
Retained Earnings	-4.4%	-697	-668	-667	-647	-616	-601	-577	-558	-545	-541	-544	-536	-539	-453	-441	-405	-383	-357	-338	-314	-297
Additional Paid-In Capital	16.6%	789	676	671	657	652	648	643	638	634	629	625	620	615	450	447	394	380	369	347	340	333
Shares Outstanding	44.8%	115	79.00	79.00	78.00	77.00	77.00	77.00	77.00	76.00	77.00	76.00	76.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	406	-	-	-	284	-	-	-	1,079	-	-	-	478	-	-	-	169	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-190.4%	-22,454	-7,732	-20,075	-19,973	-16,958	-13,169	-10,876	-18,600	-15,153	-12,982	-20,056	-17,359	-6,246	-13,658	-14,796	-18,854	-19,467	-19,544	-19,181	-19,386	-13,648
Share Based Compensation	-4.1%	4,328	4,512	4,413	4,572	4,234	4,240	4,281	4,209	3,841	3,758	4,292	3,086	2,104	1,936	1,826	1,665	1,953	3,169	1,695	1,942	1,949
Cashflow From Investing	-77.2%	-459	-259	-1,990	-3,379	-2,150	-794	-495	-276	-631	-276	-129	-158	-253	-214	-125	-249	-601	-419	-493	-725	-479
Cashflow From Financing	108.3%	108,170	51,935	9,645	78.00	458	374	493	129	667	679	2,667	-1,162	163,913	220	51,063	12,818	9,091	18,612	5,338	42,300	16,328

OCUL Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Total revenue, net	$ 58,443	$ 51,494	$ 43,522
Costs and operating expenses:
Cost, Product and Service [Extensible List]	Product revenue, net	Product revenue, net	Product revenue, net
Cost of product revenue	$ 5,281	$ 4,540	$ 4,406
Research and development	61,055	53,462	50,083
Selling and marketing	40,549	39,922	35,190
General and administrative	33,940	32,224	31,880
Total costs and operating expenses	140,825	130,148	121,559
Loss from operations	(82,382)	(78,654)	(78,037)
Other income (expense):
Interest income	3,983	798	33
Interest expense	(11,338)	(7,022)	(6,671)
Change in fair value of derivative liabilities	(5,188)	13,841	78,121
Gains and losses on extinguishment of debt, net	14,190
Other income (expense), net	(1)	(1)	1
Total other income, net	1,646	7,616	71,484
Net loss	$ (80,736)	$ (71,038)	$ (6,553)
Net loss per share, basic (in dollars per share)	$ (1.01)	$ (0.92)	$ (0.09)
Weighted average common shares outstanding, basic (in shares)	79,827,362	76,875,035	76,392,870
Net loss per share, diluted (in dollars per share)	$ (1.02)	$ (0.97)	$ (0.98)
Weighted average common shares outstanding, diluted (in shares)	85,596,594	82,644,267	82,162,102
Product revenue, net
Revenue:
Total revenue, net	$ 57,870	$ 50,457	$ 43,522
Collaboration revenue
Revenue:
Total revenue, net	$ 573	$ 1,037

OCUL Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 195,807	$ 102,300
Accounts receivable, net	26,179	21,325
Inventory	2,305	1,974
Restricted cash	150
Prepaid expenses and other current assets	7,794	4,028
Total current assets	232,235	129,627
Property and equipment, net	11,739	9,856
Restricted cash	1,614	1,764
Operating lease assets	6,472	8,042
Total assets	252,060	149,289
Current liabilities:
Accounts payable	4,389	5,123
Accrued expenses and other current liabilities	28,666	24,097
Deferred revenue	255	576
Operating lease liabilities	1,586	1,599
Total current liabilities	34,896	31,395
Other liabilities:
Operating lease liabilities, net of current portion	6,878	8,678
Derivative liabilities	29,987	6,351
Deferred revenue, net of current portion	14,135	13,387
Notes payable, net	65,787	25,257
Other non-current liabilities	108	93
Convertible Notes, net	9,138	28,749
Total liabilities	160,929	113,910
Commitments and contingencies (Note 17)
Stockholders' equity:
Preferred stock, $0.0001 par value; 5,000,000 shares authorized and no shares issued or outstanding at December 31, 2023 and December 31, 2022, respectively
Common stock, $0.0001 par value; 200,000,000 shares authorized and 114,963,193 and 77,201,819 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	12	8
Additional paid-in capital	788,697	652,213
Accumulated deficit	(697,578)	(616,842)
Total stockholders' equity	91,131	35,379
Total liabilities and stockholders' equity	$ 252,060	$ 149,289

About Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. Ocular Therapeutix, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). The company was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

CEO	Mr. Antony Mattessich
WEBSITE	ocutx.com
INDUSTRY	Biotechnology
EMPLOYEES	274

Ocular Therapeutix Inc Frequently Asked Questions

What is the ticker symbol for Ocular Therapeutix Inc? What does OCUL stand for in stocks?

OCUL is the stock ticker symbol of Ocular Therapeutix Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ocular Therapeutix Inc (OCUL)?

As of Thu Apr 25 2024, market cap of Ocular Therapeutix Inc is 624.24 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OCUL stock?

You can check OCUL's fair value in chart for subscribers.

What is the fair value of OCUL stock?

You can check OCUL's fair value in chart for subscribers. The fair value of Ocular Therapeutix Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ocular Therapeutix Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OCUL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ocular Therapeutix Inc a good stock to buy?

The fair value guage provides a quick view whether OCUL is over valued or under valued. Whether Ocular Therapeutix Inc is cheap or expensive depends on the assumptions which impact Ocular Therapeutix Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OCUL.

What is Ocular Therapeutix Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 25 2024, OCUL's PE ratio (Price to Earnings) is -7.73 and Price to Sales (PS) ratio is 10.68. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OCUL PE ratio will change depending on the future growth rate expectations of investors.